A Five-Lab-Value Score Detects Alcohol-Driven Liver Disease That Patients Don't Disclose
Fatty liver disease is common, but its cause matters enormously. Liver injury driven by obesity and metabolic dysfunction follows a different trajectory and requires different management than injury caused by alcohol - and alcohol-related damage can progress silently for years if the underlying cause is missed.
The problem is that patients frequently underreport alcohol consumption, particularly in clinical settings where stigma is a concern. When someone presents with abnormal liver function tests and fatty liver on imaging, distinguishing the metabolic from the alcohol-related cause based on what the patient reports is unreliable.
A team at the University of California San Diego School of Medicine has developed a scoring tool that does not rely on patient self-report. The MetALD-ALD Prediction Index - MAPI - uses five standard laboratory values already collected during most primary care and liver clinic visits to estimate the probability that a patient's fatty liver disease is being driven by alcohol rather than metabolic factors. Results are published in Gastroenterology.
Building and validating the score
The research team developed MAPI using data from more than 500 adults in the San Diego region, then validated it in approximately 1,800 individuals from Sweden. The two-cohort design is methodologically important: a score that performs well only in the population it was built from has limited clinical utility. The Swedish validation cohort differs from the San Diego development cohort in ethnicity, healthcare setting, and dietary patterns.
MAPI outperformed commonly used blood tests in distinguishing alcohol-related liver injury from metabolic causes. The researchers designed it explicitly to identify when a more accurate but expensive alcohol biomarker test - phosphatidylethanol (PEth) - is worth ordering. PEth is highly reliable for detecting heavy alcohol use but is costly and not universally available in primary care or smaller clinical settings.
"This new score gives clinicians a simple and accessible way to uncover hidden alcohol-related liver injury," said senior author Dr. Rohit Loomba, professor of medicine at UC San Diego School of Medicine. "By improving how we classify liver disease, we can help patients achieve better long-term health outcomes."
Why the distinction matters
Fatty liver disease affects approximately one in three adults worldwide. When alcohol is the primary driver, the priority is reducing consumption - through counseling, medication, and behavioral support. Treatment strategies for metabolic liver disease focus on weight management and blood sugar control. Missed alcohol-driven damage can proceed for years without causing symptoms obvious enough to trigger reassessment.
"Our goal was to build something practical," said study first author Federica Tavaglione. "These lab values are already part of standard care, so MAPI can be implemented immediately without adding cost or complexity for clinics."
What comes next
The researchers plan to use MAPI in larger observational studies and future clinical trials. A scoring tool validated in 2,300 patients is promising but not yet at the scale that would support unreserved clinical adoption across diverse populations. The tool also cannot determine how much alcohol a patient is consuming - it flags likelihood of alcohol-related liver injury, guiding the decision to pursue confirmatory testing rather than serving as a standalone diagnostic.